These patients demonstrated a significant reduction in serum IL-6 levels, suppression of an increase in high-sensitivity C-reactive protein (hs-CRP) levels, and an improvement in their SLE disease activity scores as measured by SLEDAI-2K [76]. The gene discussed is IL6; the disease is systemic lupus erythematosus.